In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates
- 46 Downloads
From July 1987 to January 1988, 452 cefoperazone-resistant bacterial isolates were identified among strains subjected to routine susceptibility testing in a clinical microbiology laboratory. The 452 isolates were tested for susceptibility to cefoperazone, sulbactam, and a 2:1 combination of these drugs by agar dilution techniques. The greatest benefit of the cefoperazone-sulbactam combination was noted againstBacteroides spp. andAcinetobacter spp. The combination demonstrated clinically significant synergism against approximately 20% of strains ofPseudomonas aeruginosa.
KeywordsInternal Medicine Agar Bacterial Isolate Susceptibility Testing Great Benefit
Unable to display preview. Download preview PDF.
- 1.Gould, I. M., Wise, R. β-lactamase inhibitors. In: Peterson, P. K. and Verhoef, J. (ed.): Antimicrobial agents annual. Volume 3. Elsevier, Amsterdam, 1988, p. 63–76.Google Scholar
- 2.Jones, R. N., Barry, A. L., Packer, R. R., Gregory, W. W., Thornsberry, C. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination. Journal of Clinical Microbiology 1987, 25: 1725–1729.PubMedGoogle Scholar
- 3.Washington, J. A. Susceptibility tests: agar dilution. In: Lennette, E. H., Balows, A., Hausler, W. J., and Shadomy, H. J. (ed.): Manual of clinical microbiology. American Society for Microbiology, Washington, DC, 1985, p. 967–971.Google Scholar
- 6.Sirot, J., Chanal, C., Petit, A., Sirot, D., Labia, R., Gerbaud, G. Klebsiella pneumoniae and otherEnterobacteriaceae producing novel plasmid-mediated β-lactamases markedly active against third-generation cephalosporins: epidemiologic studies. Reviews of Infectious Diseases 1988, 10: 850–859.PubMedGoogle Scholar